Phase III IMpower010 study of Tecentriq consistent with previous studies in NSCLC and published in The Lancet – Genentech/Roche

Genentech/Roche presented new data from the Phase III IMpower010 study at the European Society for Medical Oncology (ESMO) Congress 2021 Presidential Symposium, reinforcing the significant disease-free survival (DFS) benefit offered by Tecentriq (atezolizumab) for people with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1 at least 1%. Data from the IMpower010 trial were published simultaneously in The […]

Lung cancer screening for survivors of head and neck cancer

Head and neck cancer survivors with long smoking histories had a 2.5-fold greater risk of developing lung cancer than those without prior head and neck cancer, according to a secondary analysis of the National Lung Screening Trial (NLST) data.1 The landmark NLST randomized more than 50,000 participants at high risk for lung cancer in a 1:1 ratio to either low-dose […]